Peculiarities of community-acquired pneumonia treatment in patients with COVID-19
DOI:
https://doi.org/10.52692/1857-0011.2021.1-69.22Keywords:
Community-acquired pneumonia, COVID-19, antibacterial therapyAbstract
The clinical picture (fever, cough, sputum, auscultatory changes), peripheral blood parameters (leukocytosis, ESR) and radiological data are currently the criteria for suspecting bacterial pneumonia in patients with SARS CoV-2 infection and for indication of antibacterial treatment. The initiation of antibiotic therapy is empirical by taking into account the pathogens most likely involved in community-acquired pneumonia (Str pneumoniae, St. aureus, Kl. pneumoniae, Haemofillus influenzae, Mecoplasma pneumoniae, Chlamydia, Ps. aeruginosa). Beta-lactams (cephalosporins, carbapenems), protected beta-lactams, macrolides and fluoroquinolones are the most commonly administered groups, and the combinations of cephalosporins + macrolides and cephalosporins + fluoroquinolones constitute the most used groups of antibacterial treatment in order to include bacterial flora, gram-positive or gram-negative, and atypicalDownloads
Published
Issue
Section
License
Copyright (c) 2021 Bulletin of the Academy of Sciences of Moldova. Medical Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.